NCT07721857Not yet recruiting
Neutrophil Extracellular Traps and Lupus Nephritis
Dynamic Changes of Neutrophil Extracellular Traps in Lupus Nephritis and Their Role in Predicting Treatment Response.
Source: ClinicalTrials.gov · Last updated 23 Jul 2026
Brief summary (registry, in English)
Lupus Nephritis is one of the most severe organ manifestations of systemic lupus erythematosus and represents a major cause of morbidity, chronic kidney disease, and long-term mortality. Despite significant advances in immunosuppressive therapies, a substantial proportion of patients fail to achieve sustained renal remission or progress to end-stage renal disease, highlighting the need for improved understanding of disease mechanisms and more reliable biomarkers for disease monitoring and therapeutic response
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 19 Jul 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 31 Aug 2028
- Lead sponsor
- Assiut University
- Diseases
- Lupus (SLE)
- NCT number
- NCT07721857
What you commit to
- Study type: Observational
- Planned participants: 100
- From 1 Sept 2026 to the primary completion date, 31 Aug 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Participants will be excluded if ANY of the following criteria apply:
- Other Kidney Diseases:
- Presence of, or suspicion of, any other primary or significant secondary kidney disease unrelated to SLE (e.g., diabetic nephropathy, hypertensive nephrosclerosis, IgA nephropathy, significant drug-induced nephrotoxicity, rheumatoid arthritis, positive HBs antigen or HCV antibody).
- Confounding Clinical Conditions:
- Presence of an active or recent major infection (e.g., sepsis, pneumonia, UTI) at the time of enrollment, as infection can significantly alter immune markers.
- Presence of advanced chronic kidney disease (CKD Stage 4 or 5) predating the diagnosis of SLE.
- 3 · Pregnancy or lactation.
- 4\. Recent use (within the last 3 months) of biologic therapies that may affect neutrophil function or NET formation.
- 5\. Use of medications known to significantly alter neutrophil activity. 6. History of malignancy.
Who the study is looking for
- Adult patients (≥ 18 and \> 60 years) of either sex.
- Fulfill the 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus (SLE) \[11\].
- Diagnosis of active lupus nephritis requiring a renal biopsy as per standard clinical indications (e.g., proteinuria ≥ 0.5 g/24h, active urinary sediment, unexplained rise in serum creatinine).
- Availability of an adequate renal biopsy specimen for histopathological evaluation according to the International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2018 classification.
- Patients planned to initiate standard induction therapy (e.g., mycophenolate mofetil or cyclophosphamide with corticosteroids).
- Provision of written informed consent.
- 1\) SLE without nephritis: Patients meeting SLE criteria without any clinical or laboratory evidence of renal involvement (normal urinalysis, proteinuria \< 0.3 g/24h, normal serum creatinine).
Age in the registry: 18 years to 60 years · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.